Please add our email address to your safe senders list or address book.
2Q 2018 | View Online
Celerion Logo
W
elcome to the latest issue of the Celerion Science Newsletter, designed to provide to our readers information on the latest technologies, trends and stories specifically focused on early clinical development activities and professionals in clinical pharmacology and associated sciences. Celerion Translates Science into Medicine, using state of the art technologies and new, innovative approaches to early clinical research. We invite you to share our vision, techniques and experiences learned through our accomplishments in all aspects of early clinical development by exchanging information, learning and progressing science.
 
Celerion Translates Science into Medicine
 

ACCOMPLISHMENTS

CRO Leadership Awards 2018
Full Press Release
 

SCIENTIFIC EXCELLENCE

Celerion Creates a Fully Automated, Early Development Clinical Trial Data Management Platform

Therapeutic Peptides for CNS Indications: Progress and Challenges

Attacking neurodegeneration and promoting neuroprotection have been the holy grail in neurology for almost 20 years and represent an area of high unmet medical need. However, indications like Alzheimer’s disease and stroke are areas in drug development fraught with failure. This review will highlight three CNS peptide programs which are tackling targets and indications in which traditional small molecule approaches have been difficult and challenging. The goal of these peptide programs is to produce selective therapeutics with a better safety profile.


Read More
Development and Validation of an ELISA for the CK18-M30 Apoptosis Biomarker for NASH Drug Development

Cystatin C is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies

Glomerular filtration rate (GFR) is routinely used as a surrogate endpoint for the development of investigational drugs in clinical trials. GFR and staging of chronic kidney disease are typically assessed by measuring the concentration of endogenous serum biomarkers such as albumin and creatinine. However,creatinine is subject to high biological variability,and levels of creatinine do not rise until nearly 50% of kidney function is damaged, leading to inaccurate chronic kidney disease staging and false negatives


Read More

 

Conference Posters


  • American Thoracic Society: A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations after Administration of either YPL-001, or Placebo in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease [View Poster]

  • World ADC Conference: Immunogenicity Assessment of Antibody Drug Conjugates in Cancer Studies [View Poster]

  • 13th Workshop on Recent Issues in Bioanalysis (WRIB) Conference: Total and Free VEGF Assays with High Drug Tolerance for the Anti-VEGF Inhibitors Avastin® Bevacizumab), Lucentis® (Ranibizumab), and Eylea® (Aflibercept) [View Poster]

  • World Vaccine Congress: A Multiplex qPCR Assay for Zika, Dengue, and Chikungunya Viruses (ZDC) to Support On-going Vaccine and Drug Efficacy Studies [View Poster]

  • American Society for Mass Spectrometry: Use of Alkaline Mobile Phase to Achieve Good Peak Shape in The Rapid Lc-MS/MS Analysis of Lisinopril in Human Plasma [View Poster]

 
ASSAY SEARCH:
Global List of Validated Bioanalytical Assays


Search Assays
FROM THE BLOG:
The Next Frontier of Pharmacology: Micro Drug Delivery


Read More
VIDEO FEATURE:
What is Celerion?


Watch the Video
INFORMATION SHEET:
NASH Bioanalytical Roadmap


Read More

 
Celerion Lab
Scientific innovations allow us to create new and better medicine for people who need it to survive.

Biomarker Qualification and Validation Challenges: The Insulin Case Study

Biomarker Qualification and Validation Challenges: The Insulin Case Study

Biomarkers follow varied paths into clinical trials for pharmaceutical development. Before implementation in clinical studies, candidate biomarkers are subjected to qualification and validation. Analytical validation ensures adequate assay performance in relation to the questions addressed in the clinical study (fit-for-purpose). Biomarker qualification entails collecting sufficient evidence of the relationship between a biomarker with the relevant biological processes and clinical end points. Biomarkers used in pharmaceutical research had not been under clear regulatory guidance until recently. The first FDA paper where biomarkers were mentioned was the PK guidance from 2013.


Read More

Evaluating cardiac risk: exposure response analysis in early clinical drug development

Evaluating Cardiac Risk: Exposure Response Analysis in Early Clinical Drug Development

The assessment of a drug’s cardiac liability has undergone considerable metamorphosis by regulators since International Council for Harmonization of Technical Requirement for Pharmaceuticals for Human Use E14 guideline was introduced in 2005. Drug developers now have a choice in how proarrhythmia risk can be evaluated; the options include a dedicated thorough QT (TQT) study or exposure response (ER) modeling of intensive electrocardiogram (ECG) captured in early clinical development. The alternative approach of ER modeling was incorporated into a guidance document in 2015 as a primary analysis tool which could be utilized in early phase dose escalation studies as an option to perform a dedicated TQT trial.


Read More
 

OUR PEOPLE

Meet J. Fred Pritchard PhD, Vice President, Global Drug Development

As Vice President of Global Drug Development, Dr. Pritchard leads a global team of drug development and regulatory affairs experts, project management professionals and alliance managers that work actively with clients to bring their drug products efficiently through early clinical testing.


Dr. Pritchard brings 30 years of drug development experience to his work, including pre-registration work on five currently marketed pharmaceuticals and several that are currently in clinical development. Leveraging his experience in leading international teams of scientists at large pharmaceutical companies, Dr. Pritchard founded and led a group of consultants and program directors within a full service CRO that collectively worked on nearly 40 integrated drug development programs, bringing several of these through IND into phase I and II clinical trials.


Dr. Pritchard has given numerous invited lectures at scientific meetings and academic institutions and is an author on over 120 scientific publications and abstracts. He is the 2000 Alumni Fellow of the Penn State College of Medicine, and named one of nine “Notable People in Pharmaceutical R&D” by R&D Directions magazine in 2009.


More About Celerion's Management Team

J. Fred Pritchard PhD, Vice President, Global Drug Development
Let's Talk
 
Celerion Events: Symposia and Conferences
Outsourcing in Clinical Trials Southern California 2018

Sep. 26-27, 2018 | La Jolla, California
Attend Our Presentation and
Visit Celerion in Booth #47


Register Now

Outsourcing in Clinical Trials DACH 2018

Oct. 9-10, 2018 | Zurich, Switzerland
Visit Celerion in Booth #7


Register Now


World Vaccine Congress Europe

Oct. 29-31, 2018 | Lisboa, Portugal
Attend Our Roundtable and
Visit Celerion in Booth #23


Register Now


Outsourcing in Clinical Trials New England 2018

Nov. 6-7, 2018 | Boston, Massachusetts
Attend Our Presentation and
Visit Celerion in Booth #34


Register Now


European Bioanalysis Forum - EBF 2018

Nov. 21-23, 2018 | Barcelona, Spain
Visit Celerion at Our Booth


Register Now

 
Celerion

+1.402.476.2811
info@celerion.com
Twitter YouTube LinkedIn
Click here to unsubscribe.